Literature DB >> 25118583

Neurofibromatosis 2 invasion of the internal auditory canal wall: clinical significance.

Joni Doherty1, John L Go, Fred H Linthicum.   

Abstract

OBJECTIVE: To describe the infiltration of severe phenotype ("Wishart") neurofibromatosis type 2 (NF2)-related vestibular nerve schwannomas (VSs) into the internal auditory canal wall in contrast to sporadic VS and the milder ("Gardner") phenotype NF2-related VS. STUDY
DESIGN: Retrospective case series involving microscopic examination and review of clinical history.
SETTING: Temporal bone laboratory, harboring 849 documented pairs of decalcified, formalin-fixed, celloidin-embedded, sectioned human temporal bones (hTBs) with clinical history. SUBJECTS AND METHODS: Histologic sections from 56 patients who had been treated by the House Clinic for VS and who had pledged their temporal bones were identified in the data base of the laboratory. Twenty-four hTBs were from individuals with NF2.Each series of sections was examined microscopically for evidence of invasion of the walls of the internal auditory canal (IAC), hearing thresholds, speech discrimination, score (SDS), and tumor recurrence.
RESULTS: Infiltration of the walls of the IAC by small buds of VS was found in 17 of the 24 NF2 hTBs. The only 2 NF2 without invasion were from an elderly patient with the milder (Gardner) form of NF2. Ten of the 12 NF2 patients had undergone surgery for the removal of their tumor, but residual tumor remained in the bone surrounding the IAC. Invasive VS were associated with poorer hearing thresholds at 250, 500, 1,000, and 2,000 Hz and lower SDS score. A relationship between invasion and recurrence was not statistically significant.
CONCLUSION: The majority of IAC tumors associated with the severe "Wishart" phenotype demonstrate bone invasion within the IAC. Invasion of bone was associated with poorer hearing. The invasive nature of NF2-associated tumors may partially explain their higher recurrence rate after resection. Surgeons managing NF2-related VS should be aware of the small infiltrations of the wall of the IAC when removing these tumors to minimize recurrence.

Entities:  

Mesh:

Year:  2014        PMID: 25118583      PMCID: PMC4165688          DOI: 10.1097/MAO.0000000000000494

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  18 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

2.  Recurrence of acoustic neuroma after incomplete resection.

Authors:  H K El-Kashlan; H Zeitoun; H A Arts; J T Hoff; S A Telian
Journal:  Am J Otol       Date:  2000-05

3.  Temporal bone histopathology in neurofibromatosis type 2.

Authors:  Sung-Il Nam; Fred H Linthicum; Saumil N Merchant
Journal:  Laryngoscope       Date:  2011-06-10       Impact factor: 3.325

4.  Usefulness of endoscope-assisted microsurgery for removal of vestibular schwannomas.

Authors:  Yoshiaki Kumon; Shohei Kohno; Shirou Ohue; Hideaki Watanabe; Akihiro Inoue; Shinji Iwata; Takanori Ohnishi
Journal:  J Neurol Surg B Skull Base       Date:  2012-02

5.  Diagnosis and management of intracochlear schwannomas.

Authors:  Alexis Bozorg Grayeli; Cyril Fond; Michel Kalamarides; Didier Bouccara; Dominique Cazals-Hatem; Françoise Cyna-Gorse; Olivier Sterkers
Journal:  Otol Neurotol       Date:  2007-10       Impact factor: 2.311

6.  Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.

Authors:  Denise S O'Keefe; Dean J Bacich; Warren D W Heston
Journal:  Prostate       Date:  2004-02-01       Impact factor: 4.104

7.  Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2.

Authors:  James R Tysome; Robert Macfarlane; Juliette Durie-Gair; Neil Donnelly; Richard Mannion; Richard Knight; Frances Harris; Zebunnisa H Vanat; Yu Chen Tam; Katherine Burton; Anke Hensiek; F Lucy Raymond; David A Moffat; Patrick R Axon
Journal:  Otol Neurotol       Date:  2012-04       Impact factor: 2.311

8.  Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.

Authors:  T Kos; S Aksoy; M A N Sendur; Z Arik; B Civelek; N Kandemir; N Y Ozdemir; N Zengin; K Altundag
Journal:  J BUON       Date:  2013 Jul-Sep       Impact factor: 2.533

9.  Genetic determinants of hearing loss associated with vestibular schwannomas.

Authors:  Konstantina M Stankovic; Maciej M Mrugala; Robert L Martuza; Michael Silver; Rebecca A Betensky; Joseph B Nadol; Anat O Stemmer-Rachamimov
Journal:  Otol Neurotol       Date:  2009-08       Impact factor: 2.311

10.  Sporadic vestibular schwannomas associated with good hearing secrete higher levels of fibroblast growth factor 2 than those associated with poor hearing irrespective of tumor size.

Authors:  Sonam Dilwali; Andrew Lysaght; Daniel Roberts; Fred G Barker; Michael J McKenna; Konstantina M Stankovic
Journal:  Otol Neurotol       Date:  2013-06       Impact factor: 2.311

View more
  2 in total

1.  An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.

Authors:  Nicolas-Xavier Bonne; Jérémie Vitte; Fabrice Chareyre; Gevorg Karapetyan; Vazgen Khankaldyyan; Karo Tanaka; Rex A Moats; Marco Giovannini
Journal:  J Neurooncol       Date:  2016-05-13       Impact factor: 4.130

2.  Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2.

Authors:  Alvin T deTorres; Carmen C Brewer; Chris K Zalewski; Kelly A King; Robert Walker; Gretchen C Scott; Ashok R Asthagiri; Prashant Chittiboina; Hung Jeffrey Kim
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.